← Back to patent-cliff list
Asciminib hydrochloride
Tier C — Watch / tradeAsciminib hydrochloride
Novartis
Originator
2021
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Bcr-Abl
Brand：Scemblix
Indications (approved)：Chronic myeloid leukaemia
Regional status
US
Approved
2021-10-29
EU
Approved
2022-08-25
China
Approved
2025-05-13
Japan
Approved
2022-03-28
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Asciminib hydrochloride?
Approved indications include: Chronic myeloid leukaemia.
When does the Asciminib hydrochloride patent expire?
No public expiry year is available for Asciminib hydrochloride yet; this page updates once verified.
How do I get a quote for Asciminib hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27